|
- Current state of biologics in treating eosinophilic esophagitis
Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if left untreated This review focuses on biologics therapy in EoE
- Biologics for eosinophilic oesophagitis: a systematic review . . .
Objective Advancing the understanding of the pathophysiology of eosinophilic oesophagitis (EoE) and other eosinophilic gastrointestinal diseases (EGIDs) has spurred research into targeted biological therapies, while the conclusive therapeutic efficacy of biologics remains uncertain In this review, we conducted a meta-analysis of all RCTS of biologics in the treatment of EoE to evaluate their
- Biologics in the Treatment of Eosinophilic Esophagitis: Ready . . .
Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including dysphagia and food impaction 1,2 The incidence and prevalence of EoE are rising and untreated disease can lead to significant esophageal stenosis 2,3 Standard treatments include proton-pump inhibitors (PPIs), swallowed topical
- DUPIXENT® (dupilumab) For Eosinophilic Esophagitis
Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb (15kg) Serious side effects can occur Please see Important Safety Information and Prescribing Information and Patient Information on website
- Biologics in eosinophilic esophagitis - PubMed
Biologics for treatment of EoE may result in symptom and histologic improvement and has the potential to treat disease with minimal side effects
|
|
|